Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dihydroaustrasulfone alcohol, also known by the code name WA-25, is a marine-derived small molecule and the synthetic precursor of austrasulfone, a natural product originally isolated from the Formosan soft coral *Cladiella australis*. It has been investigated for its potent anti-inflammatory and antioxidant properties, particularly in the context of skin diseases. Research indicates that WA-25 can alleviate atopic dermatitis (AD) by reducing skin barrier dysfunction, transepidermal water loss (TEWL), and pruritus. Its therapeutic mechanism is primarily mediated through the modulation of nucleophosmin (NPM), a protein that plays a dual role in regulating inflammatory and oxidative stress pathways. Preclinical studies suggest that WA-25 may be more effective than some current clinical standards for AD treatment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dihydroaustrasulfone alcohol.